Abstract
No public abstract is available from the verified source records.
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
A new serum type system in man—the Lp system
10.1111/j.1699-0463.1963.tb01808.x · 1963
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
10.1038/330132a0 · 1987
Genetic variants associated with Lp(a) lipoprotein level and coronary disease
10.1056/nejmoa0902604 · 2009
Extreme lipoprotein(a) levels and improved cardiovascular risk prediction
10.1016/j.jacc.2012.12.023 · 2013
Lipoprotein(a) as a cardiovascular risk factor: current status
10.1093/eurheartj/ehq386 · 2010
Genetic associations with valvular calcification and aortic stenosis
10.1056/nejmoa1109034 · 2013
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
10.1056/nejmoa1107579 · 2011
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
10.1093/eurheartj/eht055 · 2013
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)
10.1016/j.amjcard.2014.05.060 · 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
10.1016/j.jacc.2014.01.006 · 2014
Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies
10.1016/j.jacc.2012.04.038 · 2012
PCSK9 modulates the secretion but not the cellular uptake of Lipoprotein (a) ex vivo: an effect blunted by alirocumab
2016
No additional external references are available.